Payment overview · 2025
General Payments
$947.25
46 reported records · 18 companies
Healthcare provider profile · identity verified
Arnold B. Mellits, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1851343289
Verified facts
What the public records show
CMS Open Payments records show Arnold B. Mellits, MD received $947.25 in general payments during 2025 across 46 reported records.
Janssen Biotech, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $204.95 | 21.6% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $192.76 | 20.4% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.91 | 7.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $63.52 | 6.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.40 | 6.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.05 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.23 | 4.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.39 | 4.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.19 | 3.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.33 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.78 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.67 | 2.6% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $23.47 | 2.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $22.53 | 2.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.86 | 2.2% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $20.71 | 2.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.99 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.51 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $947.25 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $204.95 | 9 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $154.37 | 9 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $70.91 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $63.52 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $48.86 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.03 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $38.39 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| REAL INTELLIGENCE Normalized: real intelligence |
Device | Smith+Nephew, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| REDAPT Normalized: redapt |
Device | Smith+Nephew, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1048 | 276 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 342 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 84 |
| Simvastatin | Simvastatin | 272 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 66 |
| Bupropion Xl | Bupropion Hcl | 233 | 55 |
| Losartan Potassium | Losartan Potassium | 192 | 54 |
| Allopurinol | Allopurinol | 186 | 49 |
| Lisinopril | Lisinopril | 170 | 45 |
| Metformin Hcl | Metformin Hcl | 166 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 40 |
| Valsartan | Valsartan | 152 | 39 |
| Carvedilol | Carvedilol | 151 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 59 |
| Omeprazole | Omeprazole | 140 | 38 |
| Gabapentin | Gabapentin | 136 | 35 |
| Donepezil Hcl | Donepezil Hcl | 134 | 13 |
| Trazodone Hcl | Trazodone Hcl | 128 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 35 |
| Clonazepam | Clonazepam | 119 | 25 |
| Ezetimibe | Ezetimibe | 119 | 37 |
| Ozempic | Semaglutide | 118 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 98 | 29 |
| Memantine Hcl | Memantine Hcl | 91 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 21 |
| Mounjaro | Tirzepatide | 82 | 13 |
| Atenolol | Atenolol | 81 | 12 |
| Alendronate Sodium | Alendronate Sodium | 80 | 24 |
| Alprazolam | Alprazolam | 80 | 33 |
| Tramadol Hcl | Tramadol Hcl | 80 | 18 |
| Potassium Chloride | Potassium Chloride | 78 | 20 |
| Sertraline Hcl | Sertraline Hcl | 78 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 19 |
| Celecoxib | Celecoxib | 70 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 19 |
| Terazosin Hcl | Terazosin Hcl | 69 | 15 |
| Montelukast Sodium | Montelukast Sodium | 63 | 19 |
| Spironolactone | Spironolactone | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 61 | 18 |
| Glimepiride | Glimepiride | 60 | 16 |
| Mirtazapine | Mirtazapine | 58 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Furosemide | Furosemide | 55 | 18 |
| Methylprednisolone | Methylprednisolone | 53 | 48 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 11 |
| Ramipril | Ramipril | 51 | suppressed |
| Meloxicam | Meloxicam | 46 | 17 |
| Lorazepam | Lorazepam | 44 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 40 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 33 |
| Valacyclovir | Valacyclovir Hcl | 36 | 20 |
| Dutasteride | Dutasteride | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Jantoven | Warfarin Sodium | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 11 |
| Azithromycin | Azithromycin | 27 | 25 |
| Diazepam | Diazepam | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Prednisone | Prednisone | 24 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $947.25 · 46 records | Janssen Biotech, Inc. | Bimzelx, COSENTYX, Cologuard Collection Kit, INSPIRE, KRYSTEXXA, Kerendia, LEQEMBI, MOUNJARO, NUPLAZID, ORENCIA, OTEZLA, Ozempic, REAL INTELLIGENCE, REDAPT, REPATHA, REXULTI, Rystiggo, TERIPARATIDE, TREMFYA, TZIELD, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error